Skip to main content

Advertisement

SpringerLink
Log in

Recognizing and improving patient nonadherence to statin therapy

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Despite landmark trials demonstrating the benefits of statin therapy for lipid lowering and in the primary and secondary prevention of acute coronary events, many patients do not adhere to medication regimens. Although incremental gains have been made in lowering the absolute levels of total serum cholesterol in the general population, only one third of treated patients are achieving their lipid goals, with fewer than 20% of patients with cardiovascular disease at their target lipid goals. Only half of patients continue taking statins prescribed to them at 6 months, and only 30% to 40% continue taking them at 1 year. Predictors of poor adherence to statins are described, such as female gender and low socioeconomic status. Approaches that are physician focused and patient centered, such as frequent follow-up and serum lipid testing and better education of patients about cardiovascular disease, are suggested to offset a major impediment to achieving the full therapeutic outcomes promised by clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Rosamond W, Flegal K, Friday G, et al.: Heart disease and stroke statistics — 2007 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2007, 115:e69–e171.

    Article  PubMed  Google Scholar 

  2. Yusuf S, Hawken S, Ounpuu S, et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937–952.

    Article  PubMed  Google Scholar 

  3. Scandinavian Simvastatin Survival Study Investigators: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.

    Article  Google Scholar 

  4. Shepherd R, Cobb SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301–1307.

    Article  PubMed  CAS  Google Scholar 

  5. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996, 335:1001–1009.

    Article  PubMed  CAS  Google Scholar 

  6. LIPID Investigators: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 1998, 339:1349–1357.

    Article  Google Scholar 

  7. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  8. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340–2346.

    Article  PubMed  CAS  Google Scholar 

  9. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000, 101:207–213.

    PubMed  CAS  Google Scholar 

  10. Carroll MD, Lacher DA, Sorlie PD, et al.: Trends in serum lipids and lipoproteins of adults, 1960–2002. JAMA 2005, 294:1773–1781.

    Article  PubMed  CAS  Google Scholar 

  11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143–3421.

    Google Scholar 

  12. Simmons LA, Levis G, Simons J: Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996, 164:208–211.

    Google Scholar 

  13. Avorn J, Monette J, Lacour A, et al.: Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998, 279:1458–1462.

    Article  PubMed  CAS  Google Scholar 

  14. Benner JS, Glynn RJ, Mogun H, et al.: Long-term persistence in use of statin therapy in elderly patients. JAMA 2002, 288:455–461.

    Article  PubMed  Google Scholar 

  15. Frolkis JP, Pearce JL, Nambi V, et al.: Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002, 113:625–629.

    Article  PubMed  CAS  Google Scholar 

  16. Jackevicius CA, Mamdani M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002, 288:462–467.

    Article  PubMed  Google Scholar 

  17. Blackburn DF, Dobson RT, Blackburn JL: Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy 2005, 25:1035–1043.

    Article  PubMed  CAS  Google Scholar 

  18. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH: Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005, 165:2671–2676.

    Article  PubMed  Google Scholar 

  19. Bandolier S: Patient compliance with statins. Available at http://www.jr2.ox.ac.uk/ bandolier/ booth/cardiac/patcomp.html. Accessed September 25, 2007.

  20. Choudhry NK, Avorn J, Antman EM, et al.: Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff (Millwood) 2007, 26:186–194.

    Article  Google Scholar 

  21. Thiebaud P, Patel BV, Nichol MB: The demand for statin: the effect of copay on utilization and compliance. Health Econ 2007, In press.

  22. Gibson TB, Mark TL, Axelson K, et al.: Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 2006, 12:SP11–SP19.

    PubMed  Google Scholar 

  23. Schultz JS, O’Donnell JC, McDonough KL, et al.: Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005, 11:306–312.

    PubMed  Google Scholar 

  24. Schneeweiss S, Patrick AR, Maclure M, et al.: Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 2007, 115:2128–2135.

    Article  PubMed  CAS  Google Scholar 

  25. Wei L, MacDonald TM, Watson AD, Murphy MJ: Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiol Drug Saf 2007, 16:385–392.

    Article  PubMed  CAS  Google Scholar 

  26. Brookhart MA, Patrick AR, Schneeweiss S, et al.: Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007, 167:847–852.

    Article  PubMed  Google Scholar 

  27. Benner JS, Tierce JC, Ballantyne CM, et al.: Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004, 22(Suppl 3):13–23.

    PubMed  Google Scholar 

  28. Benner JS, Pollack MF, Smith TW, et al.: Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005, 62:1468–1475.

    Article  PubMed  CAS  Google Scholar 

  29. Pearson T, Kopin L: Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes. Prev Cardiol 2003, 6:204–211.

    Article  PubMed  CAS  Google Scholar 

  30. Weymiller AJ, Montori VM, Jones LA, et al.: Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med 2007, 167:1076–1082.

    Article  PubMed  CAS  Google Scholar 

  31. Rasmussen JN, Chong A, Alter DA: Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007, 297:177–186.

    Article  PubMed  CAS  Google Scholar 

  32. Kirsch IS, Jungeblut A, Jenkins L, Kolstad A: Adult Literacy in America: A First Look at the Findings of the National Adult Literacy Survey, edn 2. Washington, DC: Department of Education, Office of Educational Research and Improvement; 1993.

    Google Scholar 

  33. Healthy People 2010, edn 2. Washington, DC: Department of Health and Human Services; 2000.

  34. Caso G, Kelly P, McNurlan MA, Lawson WE: Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409–1412.

    Article  PubMed  CAS  Google Scholar 

  35. Thiebaud P, Patel BV, Nichol MB, Berenbeim DM: The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005, 11:670–674.

    PubMed  Google Scholar 

  36. Perreault S, Blais L, Dragomir A, et al.: Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 2005, 61:667–674.

    Article  PubMed  Google Scholar 

  37. Chapman RH, Benner JS, Petrilla AA, et al.: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005, 165:1147–1152.

    Article  PubMed  Google Scholar 

  38. Cubeddu LX, Seamon MJ: Statin withdrawal: clinical implications and molecular mechanisms. Pharmacotherapy 2006, 26:1288–1296.

    Article  PubMed  CAS  Google Scholar 

  39. Fleisher LA, Beckman JA, Brown KA, et al.: ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery.) Circulation 2007, In press.

  40. Petrilla AA, Benner JS, Battleman DS, et al.: Evidence-based interventions to improvepatient compliance with anti-hypertensive and lipid-lowering medications. Int J Clin Pract 2005, 59:1441–1451.

    Article  PubMed  CAS  Google Scholar 

  41. Lipitor: Warnings, Liver Dysfunction. Physicians’ Desk Reference, edn 61. Montvale, NJ: Thomson PDR; 2485.

    Google Scholar 

  42. Bonow RO, Smaha LA, Smith SC Jr, et al.: World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002, 106:1602–1605.

    Article  PubMed  Google Scholar 

  43. Brookhart MA, Patrick AR, Dormuth C, et al.: Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007, 166:348–354.

    Article  PubMed  Google Scholar 

  44. Chaudhry HJ, Grieco AJ, Macklis RM, et al.: Fundamentals of Clinical Medicine, edn 4. Philadelphia: Lippincott Williams & Wilkins; 2004:33–39.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Suffolk County Department of Health Services, Office of the Commissioner, 225 Rabro Drive East, Hauppauge, NY, 11788, USA

    Humayun J. Chaudhry

Authors
  1. Humayun J. Chaudhry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian McDermott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Humayun J. Chaudhry.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaudhry, H.J., McDermott, B. Recognizing and improving patient nonadherence to statin therapy. Curr Atheroscler Rep 10, 19–24 (2008). https://doi.org/10.1007/s11883-008-0004-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-008-0004-4

Keywords

Search

Navigation